Growing Shareholder Value

Events & Presentations

Upcoming Events

There are currently no events to display.

Archived Events and Presentations

Date Event Details Remind Me
Summary Toggle Nov 1, 2018 at 8:00 AM EDT Nov 1, 2018
8:00 AM EDT
Summary Toggle Nov 12, 2018
Summary Toggle Jan 07, 2019
Summary Toggle Jan 31, 2019 at 8:00 AM EST Jan 31, 2019
8:00 AM EST
Summary Toggle May 2, 2019 at 8:00 AM EDT May 2, 2019
8:00 AM EDT
Summary Toggle Aug 1, 2019 at 8:00 AM EDT Aug 1, 2019
8:00 AM EDT
Summary Toggle Sep 26, 2019
Summary Toggle Oct 31, 2019 at 8:00 AM EDT Oct 31, 2019
8:00 AM EDT
Summary Toggle Jan 14, 2020
Summary Toggle Feb 6, 2020 at 8:00 AM EST Feb 6, 2020
8:00 AM EST
Summary Toggle Apr 30, 2020 at 8:00 AM EDT Apr 30, 2020
8:00 AM EDT
Summary Toggle May 27, 2020 at 8:30 AM EDT May 27, 2020
8:30 AM EDT
Summary Toggle Aug 6, 2020 at 8:00 AM EDT Aug 6, 2020
8:00 AM EDT
Summary Toggle Aug 12, 2020 at 8:00 AM EDT Aug 12, 2020
8:00 AM EDT

Location

Beauport Hotel 55 Commercial Street, Gloucester, Massachusetts 01930
Summary Toggle Oct 20, 2020 at 8:00 AM EDT Oct 20, 2020
8:00 AM EDT
Summary Toggle Oct 29, 2020 at 8:00 AM EDT Oct 29, 2020
8:00 AM EDT
FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including, without limitation, statements regarding development of Abiomed's existing and new products, the company's progress toward commercial growth, and future opportunities and expected regulatory approvals. All statements, other than statements of historical facts, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. The company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including, without limitation: the scope, scale and duration of the impact of the COVID-19 pandemic, the company’s dependence on Impella® products for all of its revenues; the company’s ability to successfully compete against its existing or potential competitors; the acceptance of the company’s products by cardiac surgeons and interventional cardiologists; long sales and training cycles associated with expansion into new hospital cardiac centers; reduced market acceptance of the company’s products due to lengthy clinician training process; the company’s ability to effectively manage its growth; the company’s ability to successfully commercialize its products; the company’s ability to obtain regulatory approvals and market and sell its products in certain jurisdictions; enforcement actions and product liability suits relating to off-label uses of the company’s products; unsuccessful clinical trials or procedures relating to products under development; the company’s ability to maintain compliance with regulatory requirements; the failure of third-party payers to provide reimbursement of the company’s products; the company’s ability to increase manufacturing capacity to support continued demand for its products; the company or its vendors’ failure to achieve and maintain high manufacturing standards; the failure of the company’s suppliers to provide the components the company requires; the company’s ability to expand its direct sales activities into international markets; the outcome of ongoing securities class action litigation relating to our public disclosures, the company’s ability to integrate acquired companies into its operations and other risks and challenges detailed in the company's filings with the Securities and Exchange Commission (the “SEC”), including the most recently filed Annual Report on Form 10-K and the filings subsequently filed with or furnished to the SEC. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. Unless otherwise required by law, the company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.